Pantera Lux paclitaxel releasing balloon for restonic coronary artery lesions after drug-eluting or bare metal stenting shows positive results

111

Six-month results from the DELUX registry and 12-month results from the PEPPER study, both demonstrated excellent safety and efficacy results for the Pantera Lux paclitaxel releasing balloon (Biotronik). Data were presented by Ralph Toelg, Segeberger Heart Center Clinic, Bad Segeberg, Germany, and Christoph Hehrlein, University Medical Center, Freiburg, Germany, respectively, at the Transcatheter Cardiovascular Therapeutics (TCT) 2011, in San Francisco, USA. 

The Pantera Lux paclitaxel releasing balloon is a novel treatment for restenotic coronary artery lesions after drug-eluting or bare metal stenting. The device is based on the highly deliverable Pantera semicompliant balloon, which is then coated with a matrix of proven antiproliferative paclitaxel and the biocompatible butyryl-tri-hexyl citrate (BTHC) excipient—enabling an optimal drug transfer to the target lesion tissue.


DELUX is a prospective, multicentre, nonrandomised, international registry evaluating the Pantera Lux paclitaxel releasing balloon, originally in 601 patients in a real-world setting, a scope which was then amended to include 1,000 patients. The primary endpoint was the 6-month cumulative major adverse coronary events (MACE) rate defined as a composite of all death, nonfatal myocardial infarction and clinically driven target vessel revascularisation. Major secondary outcomes are cumulative MACE rates at 1 and 12 months.


The DELUX 6-month outcomes confirm safety and efficacy with low revascularisation and myocardial infarction rates with MACE rates low for both the total cohort as well as the 10% of de novo lesions treated with 10.5% and 10.7% respectively.


“The Pantera Lux has proven an invaluable tool for the difficult-to-treat in-stent restenosis (ISR) lesions where conventional therapy options reach their limits,” commented Ralph Toelg. “This device is very deliverable and easy to use compared with other technologies and therapy options on the market addressing such types of challenging lesion subsets.”


The PEPPER study is a prospective, multicentre, nonrandomised, European, first-in-man clinical trial evaluating the safety and efficacy of the Pantera Lux paclitaxel releasing balloon in 81 patients. The primary endpoint was 6-month in-stent late lumen loss. Major secondary outcomes are cumulative MACE rates at 1, 6 and 12 months; in-segment late luminal loss; and percent diameter restenosis and binary restenosis at the 6-month follow-up.


The PEPPER 12-month outcomes are very favorable in a challenging in-stent restenosis patient population, with clinically driven revascularisations necessary in only 9.2% of the target lesions. This confirms the positive results seen at six months where the study’s primary endpoint of in-stent late lumen loss of 0.07 mm showed effective inhibition of neointimal proliferation in all patients including the 47% who suffered restenosis from drug-eluting stents.

 

(Visited 6 times, 1 visits today)